In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

Heather James, 66, revealed she was 'naive' about her daughter's cancer diagnosis and thought she would be 'fine' after six ...

Abu Dhabi, UAE: Sheikh Shakhbout Medical City (SSMC), one of the UAE’s largest hospitals for serious and complex care and a ...

EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its continued development as the first microbial therapy fo ...

Nordic Bioscience, a leading biomarker company, announced that its CPa9-HNE biomarker assay received a Letter of Support (LoS ...

A randomized controlled trial finds no clear benefit of adding bezlotoxumab to FMT in patients with IBD and recurrent C difficile infection.